Cost regulators have approved the routine use of Boehringer Ingelheim’s Ofev as a treatment for some patients with lung-scarring disease, idiopathic pulmonary fibrosis, on the NHS in England and Wales.
The National Institute for Health and Care excellence have drafted guidelines for the treatment of recurrent ovarian cancer, which recommend two therapies for NHS use but have also rejected a further three drugs.
After an initial rejection earlier this year, NICE has published the final draft guidance backing the use of Santen’s eye drug Ikervis on the NHS in England and Wales. The Institute is now endorsing Ikervis (ciclosporin) to treat severe keratitis in adults with dry eye disease that has not improved despite treatment with artificial tears.
England and Wales’ cost regulator, NICE, have released draft regulatory guidance recommending the expanded use of Boehringer Ingelheim’s clot buster drug Pradaxa on the National Health Service (NHS). The National Institute for Health and Care Excellence (NICE) has endorsed the drug to treat and prevent recurrent and potentially fatal blood clots in the legs and
The Welsh government has recommended Celgene’s Abraxane to treat pancreatic cancer on the National Health Service (NHS) in Wales. Specifically, Abraxane (nab-paclitaxel) has been approved by the All Wales Medicines Strategy Group as an option for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Mark
Lung cancer patients in England and Wales could gain access to a new treatment after cost regulators, NICE, have recommended Boehringer Ingelheim’s targeted therapy Giotrif (afatinib). The National Institute for Health and Care Excellence (NICE) has published draft regulatory guidance recommending Giotrif as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC),
England and Wales’ cost regulator, NICE, have published draft guidance recommending that Bristol-Myers Squibb’s Yervoy (ipilimumab) should only be used by the National Health Service (NHS) for patients in clinical trials, as current evidence is lacking. The regulatory body has already approved the skin cancer drug as a second-line treatment for advanced malignant melanoma, but
Alimera Sciences yesterday announced that the Scottish Medicines Consortium (SMC) has approved Iluvien as a treatment for chronic diabetic macular oedema (DME) for restricted use within the NHS in the country. Use of Iluvien will be restricted to patients in whom the affected eye is pseudophakic, meaning that they have an artificial lens after cataract
NHS cost regulatory body, NICE, have today published updated draft guidance, proposing to stop backing the second-line use of Tarceva (erlotinib) to treat relapsed non-small cell lung cancer (NSCLC). Following a review of the existing guidance the National Institute for Health and Care Excellence (NICE) has decided that treatment after first-line therapy has failed is